Genprex (NASDAQ: GNPX) is conducting its Phase 1/2 Acclaim-1 clinical trial evaluating the safety and efficacy of combining REQORSA(R), the company’s innovative drug candidate, in combination with Tagrisso(R) in patients with advanced EGFR mutant non-small cell lung cancer (“NSCLC”) who have experienced disease progression after previous treatments. “REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC,” a recent article explains. “During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment.
However, the findings also have revealed promising efficacy results. One patient previously treated with standard-of-care therapies such as osimertinib had a partial remission (‘PR’) by investigator evaluation and treatment is ongoing after 16 cycles, which is approximately 10.5 months. Another patient previously treated with osimertinib has stable disease and treatment is ongoing after 14 cycles, or approximately 9 months. The extended and ongoing progression free survival (‘PFS’) of each of these patients is significantly greater than the median PFS observed from treatment with osimertinib alone in this treatment setting in several prior clinical trials and is consistent with long-term PFS seen in prior clinical trials of REQORSA. These findings underscore the potential of REQORSA in reshaping the landscape of non-small cell lung cancer.”
To view the full article, visit https://ibn.fm/bAKnq
About Genprex Inc.
Genprex is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX(R) Nanoparticle Delivery System, which encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The company’s lead product candidate, REQORSA(R) (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (“NSCLC”) and small cell lung cancer (“SCLC”). Both NSCLC clinical programs received a Fast Track Designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an adeno-associated virus (“AAV”) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. For more information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
